Alternative pharmacokinetics of S-1 components, 5-fluorouracil, dihydrofluorouracil and α-fluoro-β-alanine after oral administration of S-1 following total gastrectomy

Cancer Science

Volumn 98, Issue 10, 2007, Pages 1604-1608

  Kim, Woo Young ^a   Nakata, Bunzo ^a   Hirakawa, Kosei ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE; ALPHA FLUORO BETA ALANINE; ANTINEOPLASTIC AGENT; DIHYDROFLUOROURACIL; FLUOROPYRIMIDINE S 1; FLUOROURACIL; FLUOROURACIL DERIVATIVE; OXONATE POTASSIUM; TEGAFUR; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER ADJUVANT THERAPY; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG STRUCTURE; DRUG URINE LEVEL; HUMAN; LEUKOPENIA; MAXIMUM PLASMA CONCENTRATION; POSTOPERATIVE CARE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; SINGLE DRUG DOSE; STOMACH CANCER; STRUCTURE ANALYSIS; TIME TO MAXIMUM PLASMA CONCENTRATION; TOTAL STOMACH RESECTION;

ADMINISTRATION, ORAL; ADULT; AGED; AREA UNDER CURVE; BETA-ALANINE; DRUG COMBINATIONS; FLUOROURACIL; GASTRECTOMY; HUMANS; MIDDLE AGED; OXONIC ACID; STOMACH NEOPLASMS; TEGAFUR;

EID: 34548187286     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2007.00573.x     Document Type: Article

References (22)

1. Nagashima F, Ohtsu A, Yoshida S, Ito K. Japanese nationwide post-marketing survey of S-1 in patients with advanced gastric cancer. Gastric Cancer 2005; 8: 6-11.
2. Shirasaka T, Shimamoto Y, Fukushima M. Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 1993; 53: 4004-9.
3. Okeda R, Shibutani M, Matsuo T, Kuroiwa T, Shimokawa R, Tajima T. Experimental neurotoxicity of 5-fluorouracil and its derivatives is due to poisoning by the monofluorinated organic metabolites, monofluoroacetic acid and α-fluoro-β-alanine. Acta Neuropathol 1990; 81: 66-73.
4. Muneoka K, Shirai Y, Yokoyama N, Wakai T, Hatakeyama K. 5-Fluorouracil cardiotoxicity induced by α-fluoro-β-alanine. Int J Clin Oncol 2005; 10: 441-3.
5. Kinoshita T, Nashimoto A, Yamamura Y et al. Feasibility study of adjuvant chemotherapy with S-1 (TS-1; FT, gimeracil, oteracil potassium) for gastric cancer. Gastric Cancer 2004; 7: 104-9.
6. Nakata B, Mitachi Y, Tsuji A et al. Combination therapy of a novel oral fluorouracil derivative S-1 with low-dose cisplatin for unresectable and recurrent gastric cancer: A multicenter phase I study. Clin Cancer Res 2004; 10: 1664-9.
7. Yoshida K, Ninomiya M, Takakura N et al. Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Clin Cancer Res 2006; 12: 3402-7.
8. Ueda Y, Yamagishi H, Ichikawa D et al. Phase I study of a combination of S-1 and weekly paclitaxel in patients with advanced or recurrent gastric cancer. Oncology 2005; 69: 261-8.
9. Inokuchi M, Yamashita T, Yamada H et al. Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancer. Br J Cancer 2006; 94: 1130-5.
10. Matsushima E, Yoshida K, Kitamura R, Yoshida K. Determination of S-1 (combined drug of FT, 5-chloro-2,4-dihydroxypyridine and potassium oxonate) and 5-fluorouracil in human plasma and urine using high-performance liquid chromatography and gas chromatography-negative ion chemical ionization mass spectrometry. J Chromatogr B 1997; 691: 95-104.
11. Yamada Y, Hamaguchi T, Goto M et al. Plasma concentration of 5-fluorouracil and F-β-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil. Br J Cancer 2003; 89: 816-20.
12. Takechi T, Uchida J, Fujioka A, Fukushima M. Enhancing 5-fluorouracil cytotoxicity by inhibiting dihydropyrimidine dehydrogenase activity with uracil in human tumor cells. Int J Oncol 1997; 11: 1041-4.
13. Hayashi K, Isobe Y, Honda I et al. Gastric cancer treated in 1991 in Japan: Data analysis of nationwide registry. Gastric Cancer 2006; 9: 51-66.
14. Hundahl SA, Menck HR, Mansour EG, Winchester DP. The national cancer data base report on gastric carcinoma. Cancer 1997; 80: 2333-41.
15. Hirata K, Horikoshi N, Aiba K et al. Pharmacokinetics study of S-1, a novel oral fluorouracil antitumor drug. Clin Cancer Res 1999; 5: 2000-5.
16. Tsuruoka Y, Kamano T, Kitajima M et al. Effect of gastrectomy on the pharmacokinetics of 5-fluorouracil and gimeracil after oral administration of S-1. Anti-Cancer Drug 2006; 17: 393-9.
17. Fety R, Rolland F, Barberi-Heyob M et al. Clinical impact of pharmacokinetically guided dose adaptation of 5-fluorouracil: Results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas. Clin Cancer Res 1998; 4: 2039-45.
18. Ajani JA, Faust J, Ikeda K et al. Phase I pharmacokinetics study of S-1 plus cisplatin in patients with advanced gastric carcinoma. J Clin Oncol 2005; 23: 6957-65.
19. van Groeningen CJ, Peters GJ, Schornagel JH et al. Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors. J Clin Oncol 2000; 18: 2772-9.
20. Cohen SJ, Leichman CG, Yeslow G et al. Phase I and pharmacokinetic study of once daily oral administration of S-1 in patients with advanced cancer. Clin Cancer Res 2002; 8: 2116-22.
21. Maehara Y, Takeuchi H, Oshiro T et al. Effect of gastrectomy on the pharmacokinetics of FT, uracil, and 5-fluorouracil after oral administration of a 1: 4 FT and uracil combination. Cancer Chemother Pharmacol 1994; 33: 445-9.
22. Yoshisue K, Masuda H, Matsushima E et al. Tissue distribution and biotransformation of potassium oxonate after oral administration of a novel antitumor agent (drug combination of FT, 5-chloro-2,4-dihydroxypyridine, and potassium oxonate) to rats. Drug Metab Dispos 2000; 28: 1162-7.